ARES vs. VRNA
ARES (Ares Management Corporation) and VRNA (Verona Pharma plc) are both stocks. ARES operates in Asset Management (Financial Services), while VRNA operates in Biotechnology (Healthcare). At a 0.16 correlation, their price movements are largely independent.
Performance
ARES vs. VRNA - Performance Comparison
Loading charts...
Returns By Period
ARES
- 1D
- -4.07%
- 1M
- -1.32%
- YTD
- -23.01%
- 6M
- -26.26%
- 1Y
- -23.41%
- 3Y*
- 13.92%
- 5Y*
- 18.72%
- 10Y*
- 29.90%
VRNA
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ARES vs. VRNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARES Ares Management Corporation | -23.01% | -5.72% | 52.68% | 79.52% | -12.75% | 77.75% | 37.37% | 110.13% | -5.54% | 8.28% |
VRNA Verona Pharma plc | 0.00% | 130.21% | 133.60% | -23.92% | 288.84% | -4.00% | 21.74% | -40.41% | -18.71% | -12.07% |
Correlation
The correlation between ARES and VRNA is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017 | 0.16 |
The correlation between ARES and VRNA shifts across timeframes, from -0.04 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
ARES:
$2.83
VRNA:
-$0.69
ARES:
4.21
VRNA:
57.97
ARES:
$6.31B
VRNA:
$167.65M
ARES:
$4.46B
VRNA:
$159.52M
ARES:
$2.42B
VRNA:
-$40.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARES vs. VRNA — Risk / Return Rank
ARES
VRNA
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
ARES vs. VRNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ares Management Corporation (ARES) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARES | VRNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 0.93 | — | — |
| Calmar ratioReturn relative to maximum drawdown | -0.48 | — | — |
| Martin ratioReturn relative to average drawdown | -0.92 | — | — |
Loading charts...
Drawdowns
ARES vs. VRNA - Drawdown Comparison
Loading charts...
Drawdown Indicators
| ARES | VRNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -49.73% | — | — |
Max Drawdown (1Y)Largest decline over 1 year | -49.05% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -49.73% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -49.73% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -49.73% | — | — |
Current DrawdownCurrent decline from peak | -35.17% | — | — |
Average DrawdownAverage peak-to-trough decline | -11.36% | — | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.42% | — | — |
Volatility
ARES vs. VRNA - Volatility Comparison
Loading charts...
Volatility by Period
| ARES | VRNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.55% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 35.66% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 41.79% | — | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 37.52% | — | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 36.74% | — | — |
Dividends
ARES vs. VRNA - Dividend Comparison
ARES's dividend yield for the trailing twelve months is around 5.49%, while VRNA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARES Ares Management Corporation | 5.49% | 3.29% | 2.10% | 2.59% | 3.57% | 2.31% | 3.40% | 3.59% | 7.50% | 5.65% | 4.32% | 6.81% |
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
ARES vs. VRNA - Financials Comparison
This section allows you to compare key financial metrics between Ares Management Corporation and Verona Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARES vs. VRNA - Profitability Comparison
ARES - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported a gross profit of 1.47B and revenue of 1.53B. Therefore, the gross margin over that period was 96.1%.
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.
ARES - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported an operating income of 364.95M and revenue of 1.53B, resulting in an operating margin of 23.8%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.
ARES - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported a net income of 142.59M and revenue of 1.53B, resulting in a net margin of 9.3%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.
Frequently Asked Questions
ARES and VRNA have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for ARES and VRNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer